The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Differential expression and responsiveness of chemokine receptors (CXCR1–3) by human microvascular endothelial cells and umbilical vein endothelial cells
Abstract
The basis for the angiogenic effects of CXC chemokines such as interleukin 8 (IL‐8) and for angiostatic chemokines such as interferon‐inducible protein 10 (IP‐10) has been difficult to assess. We recently reported, based on an RNase protection assay, that human umbilical vein endothelial cells (HUVECs) did not express detectable mRNA for the IL‐8 receptors CXCR1 and CXCR2. This raised the possibility of heterogeneity of receptor expression by different endothelial cell (ECs) types. Since systemic angiogenesis induced by IL‐8 would more likely involve microvessel ECs, we investigated CXC receptor expression on human microvascular dermal endothelial cells (HMECs). By confocal microscopy and immunofluorescence we observed that HMECs consistently expressed high levels of CXCR1 and CXCR4 (mean fluorescence intensity of 261 ±22.1 and 306.2±19, respectively) and intermediate levels of CXCR3 and CXCR2 (173.9±30.2 and 156±30.9, respectively). In contrast, only a small proportion of HUVEC preparations expressed low levels of CXCR1, ‐2, and ‐3 (66±19.9; 49±15, and 81.4±17.9, respectively). However, both HMECs and HUVECs expressed equal levels of CXCR4. As expected, HMECs had more potent chemotactic responses to IL‐8 than HUVECs, and this was correlated with the levels of IL‐8 receptors on the ECs. Antibodies to CXCR1 and CXCR2 each had inhibitory effects on chemotaxis of HMECs to IL‐8, indicating that both IL‐8 receptors contributed to the migratory response of these cells toward IL‐8. Assessment of the functional capacity of CXCR3 unexpectedly revealed that HMECs migrated in response to relatively higher concentrations (100–500 ng/ml) of each of the ‘angiostatic’ chemokines IP‐10, ITAC, and MIG. Despite this, the ‘angiostatic’ chemokines inhibited the chemotactic response of HMECs to IL‐8. IL‐8 and SDF‐1α but not IP‐10 induced calcium mobilization in adherent ECs, suggesting that signaling events associated with calcium mobilization are separable from those required for chemotaxis. Taken together, our data indicated that functional differences among EC types is dependent on the level of the expression of CXC chemokine receptors. Whether this heterogeneityin receptor expression by ECs reflects distinct differentiation pathways remains to be established.—Salcedo, R., Resau, J. H., Halverson, D., Hudson, E. A., Dambach, M., Powell, D., Wasserman, K., Oppenheim, J. J. Differential expression and responsiveness of chemokine receptors (CXCR1–3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J. 14, 2055–2064 (2000)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Interleukin-8 as a macrophage-derived mediator of angiogenesis
Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., DiPietro, L. A., Elner, V. M., Elner, S. G., & Strieter, R. M. (1992) · Science · doi:10.1126/science.1281554 · Cited by 2,135
The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis
Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriott, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.27348 · Cited by 1,222
Engelhardt, E., Toksoy, A., Goebeler, M., Debus, S., Bröcker, E.-B., & Gillitzer, R. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65699-4 · Cited by 435
Cited by
Li, A., Dubey, S., Varney, M. L., Dave, B. J., & Singh, R. K. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3369 · Cited by 1,332
Dufour, J. H., Dziejman, M., Liu, M. T., Leung, J. H., Lane, T. E., & Luster, A. D. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.7.3195 · Cited by 1,075
The roles of IFNγ in protection against tumor development and cancer immunoediting
Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00038-7 · Cited by 899
CXC chemokines in angiogenesis
Belperio, J. A., Keane, M. P., Arenberg, D. A., Addison, C. L., Ehlert, J. E., Burdick, M. D., & Strieter, R. M. (2000) · Journal of Leukocyte Biology · doi:10.1189/jlb.68.1.1 · Cited by 804
The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis
Brat, D. J., Bellail, A. C., & Van Meir, E. G. (2005) · Neuro-Oncology · doi:10.1215/s1152851704001061 · Cited by 760
Lasagni, L., Francalanci, M., Annunziato, F., Lazzeri, E., Giannini, S., Cosmi, L., Sagrinati, C., Mazzinghi, B., Orlando, C., Maggi, E., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021897 · Cited by 739
Interleukin-12 in anti-tumor immunity and immunotherapy
Colombo, M. P., & Trinchieri, G. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00032-6 · Cited by 685
Role of chemokines in tumor growth
Raman, D., Baugher, P. J., Thu, Y. M., & Richmond, A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.05.013 · Cited by 578
Heidemann, J., Ogawa, H., Dwinell, M. B., Rafiee, P., Maaser, C., Gockel, H. R., Otterson, M. F., Ota, D. M., Lügering, N., Domschke, W., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208231200 · Cited by 476
CXCR7 Functions as a Scavenger for CXCL12 and CXCL11
Naumann, U., Cameroni, E., Pruenster, M., Mahabaleshwar, H., Raz, E., Zerwes, H.-G., Rot, A., & Thelen, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009175 · Cited by 470
Leukocyte extravasation: chemokine transport and presentation by the endothelium
Middleton, J., Patterson, A. M., Gardner, L., Schmutz, C., & Ashton, B. A. (2002) · Blood · doi:10.1182/blood.v100.12.3853 · Cited by 456
CXC chemokines in angiogenesis
Strieter, R. M., Burdick, M. D., Gomperts, B. N., Belperio, J. A., & Keane, M. P. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.04.007 · Cited by 414
Cancer CXC chemokine networks and tumour angiogenesis
Strieter, R. M., Burdick, M. D., Mestas, J., Gomperts, B., Keane, M. P., & Belperio, J. A. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.006 · Cited by 410
CXC chemokines: the regulatory link between inflammation and angiogenesis
Romagnani, P., Lasagni, L., Annunziato, F., Serio, M., & Romagnani, S. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.02.006 · Cited by 409
Romagnani, P., Annunziato, F., Lasagni, L., Lazzeri, E., Beltrame, C., Francalanci, M., Uguccioni, M., Galli, G., Cosmi, L., Maurenzig, L., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9775 · Cited by 379
The Role of Chemokines in Melanoma Tumor Growth and Metastasis
Payne, A. S., & Cornelius, L. A. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.01725.x · Cited by 361
SALCEDO, R., & OPPENHEIM, J. J. (2003) · Microcirculation · doi:10.1038/sj.mn.7800200 · Cited by 328
Self-citationEndothelial cell heterogeneity
Aird, W. C. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000057847.32590.c1 · Cited by 324
Li, A., Varney, M. L., Valasek, J., Godfrey, M., Dave, B. J., & Singh, R. K. (2005) · Angiogenesis · doi:10.1007/s10456-005-5208-4 · Cited by 285
The role of CXC chemokines in pulmonary fibrosis
Strieter, R. M., Gomperts, B. N., & Keane, M. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30562 · Cited by 273
Korbecki, J., Kojder, K., Kapczuk, P., Kupnicka, P., Gawrońska-Szklarz, B., Gutowska, I., Chlubek, D., & Baranowska-Bosiacka, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020843 · Cited by 273
The multifaceted roles of chemokines in malignancy
Ben-Baruch, A. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9003-5 · Cited by 259
Eotaxin (CCL11) Induces In Vivo Angiogenic Responses by Human CCR3+ Endothelial Cells
Salcedo, R., Young, H. A., Ponce, M. L., Ward, J. M., Kleinman, H. K., Murphy, W. J., & Oppenheim, J. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7571 · Cited by 257
Self-citationRole of Chemokines in Endocrine Autoimmune Diseases
Rotondi, M., Chiovato, L., Romagnani, S., Serio, M., & Romagnani, P. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0044 · Cited by 257
The chemokine system – a major regulator of angiogenesis in health and disease
ROSENKILDE, M. M., & SCHWARTZ, T. W. (2004) · APMIS · doi:10.1111/j.1600-0463.2004.apm11207-0808.x · Cited by 255
CXCR2 antagonists for the treatment of pulmonary disease
Chapman, R. W., Phillips, J. E., Hipkin, R. W., Curran, A. K., Lundell, D., & Fine, J. S. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.005 · Cited by 214
Chemokines as mediators of neovascularization
Keeley, E. C., Mehrad, B., & Strieter, R. M. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.162925 · Cited by 192
CXC chemokines located in the 4q21 region are up-regulated in breast cancer
Bieche, I., Chavey, C., Andrieu, C., Busson, M., Vacher, S., Le Corre, L., Guinebretiere, J.-M., Burlinchon, S., Lidereau, R., & Lazennec, G. (2007) · Endocrine Related Cancer · doi:10.1677/erc.1.01301 · Cited by 183
Metadata
- Authors
- Salcedo, R., Resau, J. H., Halverson, D., Hudson, E. A., Dambach, M., Powell, D., Wasserman, K., & Oppenheim, J. J.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2000-10
- Volume
- 14
- Issue
- 13
- Pages
- 2055-2064
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1984802192
- Cited by
- 245
- References
- 5
- FWCI
- 8.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.